DLC1 and cancer: Because epigenetic modifications are the main cause of DLC1 down-regulation and inactivation, therapy based on the ability of DNA methyl-transferase and histone deacetylase inhibitors (HDAC) to restore DLC1 expression in cancer cells has been highlighted as an attractive therapeutic approach (54).